Norges Bank’s Metagenomi Therapeutics MGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-252,310
Closed -$598K – 1631
2025
Q3
$598K Hold
252,310
– – ﹤0.01% 1471
2025
Q2
$373K Hold
252,310
– – ﹤0.01% 1652
2025
Q1
$343K Sell
252,310
-107,892
-30% -$257K ﹤0.01% 1705
2024
Q4
$1.3M Hold
360,202
– – ﹤0.01% 1730
2024
Q3
$782K Hold
360,202
– – ﹤0.01% 1755
2024
Q2
$1.47M Buy
360,202
+252,310
+234% +$1.73M ﹤0.01% 1771
2024
Q1
$1.14M Buy
+107,892
New +$1.24M ﹤0.01% 1786

Other funds holding MGX

Norges Bank's MGX Position: Q4 2025 in Review

Norges Bank sold out of Metagenomi Therapeutics (MGX) in Q4 2025, closing a stake of 252,310 shares — an estimated $598K sold.

Norges Bank first reported a position in MGX in Q1 2024 and held it in 7 quarters. The position peaked at $1.47M in Q2 2024. 56 funds tracked by Wall St. Rank hold MGX as of Q4 2025.

  • Norges Bank reported no remaining Metagenomi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Norges Bank sold 252,310 Metagenomi Therapeutics shares in Q4 2025, an estimated $598K.
  • Norges Bank first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 7 quarters.
  • Norges Bank's Metagenomi Therapeutics position peaked at $1.47M in Q2 2024.
  • 56 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2025.

Based on Norges Bank's 13F filing for Q4 2025, filed 10 Feb 2026.